VaxAlta

What VaxAlta does

VaxAlta is a privately held glycoconjugate vaccine research and development company founded in 2013 and headquartered in Edmonton, Canada. Its stated focus is the discovery and development of glycoconjugate vaccines, a class of vaccines in which polysaccharide antigens are covalently linked to a carrier protein to elicit T-cell-dependent immune responses. This places the company in a specialized segment of vaccinology, typically targeting pathogens where plain polysaccharide vaccines have historically produced weak or non-durable immunity, such as encapsulated bacteria.

The input contains no disclosed information on VaxAlta's specific product candidates, pipeline stage, target indications, underlying conjugation chemistry, or platform architecture. The company's website (vaxalta.com) is a non-functional verification placeholder, and the only documented capital event is a 2016 grant from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), a non-dilutive Canadian federal R&D support program, with no disclosed dollar value. There are no recorded management team members, headcount figures, partnerships, patents, regulatory filings, or revenue figures in the data set, which collectively represents a material information gap for any commercial or scientific assessment.

Name

VaxAlta

Website

https://vaxalta.com

Company type

Private

Founded year

2013

Operating status

Operating

Short description

VaxAlta is a privately held Canadian biotech founded in 2013 in Edmonton that conducts research and development on glycoconjugate vaccines. The company has no disclosed products, pipeline, or revenue, and its public website is a non-functional placeholder.

Ownership category

akta.pro rank

Headquarters

HQ city

Edmonton

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

VaxAlta is a glycoconjugate vaccine research and development company that develops conjugate-based vaccine technology. The company focuses on R&D of glycoconjugate vaccine formulations combining carbohydrate antigens with carrier proteins for biomedical applications. Founded in 2013 and based in Edmonton, Canada, VaxAlta operates as a privately held for-profit entity in the biopharmaceutical sector.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• VBI Vaccines: VBI Vaccines is a vaccine R&D biotech that has developed glycoconjugate-adjuvanted and enveloped VLP platforms for infectious disease targets. It is the closest publicly traded small-cap comparability to a focused glycoconjugate vaccine R&D company.

Broad incumbents

• Novavax: Novavax is a commercial-stage vaccine specialist using recombinant nanoparticle technology. As an established vaccine developer with manufacturing scale and global commercialization capabilities, it represents the broader incumbent pathway that a successful VaxAlta platform could pursue.
• Sanofi Pasteur: Sanofi Pasteur is the vaccines division of Sanofi and one of the largest global vaccine manufacturers, with deep glycoconjugate franchise assets. It is a realistic acquirer/partner for a niche Canadian glycoconjugate R&D company.
• GSK: GSK is one of the world's largest vaccine manufacturers and acquired the glycoconjugate specialist GlycoVaxyn in 2015. It directly operates glycoconjugate programs and remains a comparable large incumbent and likely acquirer profile.
• Merck & Co. Merck operates a major vaccines franchise (including pneumococcal conjugate products) and represents the broad-incumbent licensing/MA counterpart for any glycoconjugate platform that gains traction.
• Pfizer: Pfizer is one of the largest global vaccine manufacturers with a deep conjugate-vaccine franchise and is a recurring out-licensing counterparty and acquirer of biotech platforms in this space.
• Emergent BioSolutions: Emergent BioSolutions is a vaccine and biodefense manufacturer with established conjugate-vaccine expertise (e.g., anthrax, typhoid/typhoid Vi conjugates). Comparable because of its mixed commercial-and-government glycoconjugate product positioning.

Regional players

• IMV Inc. IMV Inc. is a Canadian clinical-stage vaccine biotech focused on immunotherapeutic and prophylactic vaccines, providing a regional (Canada) comparable in scale and stage to a small glycoconjugate R&D company.
• Entos Pharmaceuticals: Entos Pharmaceuticals is an Edmonton-based Canadian biotech, sharing VaxAlta's city and Canadian ecosystem. While focused on nucleic acid delivery, it is comparable as a small Alberta/Canadian life-science R&D peer that draws on the same regional talent and grant infrastructure.

Emerging players

• Biological E. Limited: Biological E. is an Indian vaccine manufacturer with a major glycoconjugate franchise (e.g., pneumococcal conjugate, typhoid conjugate, HPV). It is comparable to VaxAlta because it shares the glycoconjugate focus and serves global public-sector vaccine buyers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VaxAlta